Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Acute lymphoblastic leukemia recurrent / Recurrent Acute lymphoblastic leukemia / Acute, recurrent Lymphoblastic Leukaemia / Relapsed ALL / Acute, recurrent Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03147612Low-Intensity Chemotherapy and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaTreatment
NCT03136146Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaTreatment